RB1 alterations predict survival in mCRPC patients treated with Zytiga or Xtandi

TECHNOLOGY: Gene profiling

Alterations in RB1 could help predict survival in mCRPC patients treated with Zytiga or Xtandi. In 429 patients with mCRPC, analysis of whole-exome sequencing, gene expression, histopathology, survival and time on treatment with Zytiga or Xtandi identified associations between poor survival and mutations and deep deletions in RB1. Next steps could include identifying the mechanisms of resistance to Zytiga and Xtandi that are induced by RB1 alterations...